|
|
|
 |
| Location: Home -
Products - API Intermediates - API Intermediates
|
Mizoribine (Bredinin)
| Catalogue No. : |
C13897 |
| Product Name: |
Mizoribine (Bredinin) |
| Chemical Name: |
5-Hydroxy-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide |
| CAS No. : |
50924-49-7 |
| Structure : |
|
| Molecular Formula: |
C9H13N3O6 |
| Molecular Weight: |
259.22 |
| Purity: |
>99% |
| Usage: |
Mizoribine is an imidazole nucleoside immunosuppressant agent that was first isolated from the mold Eupenicillium brefeldimium with antibiotic and cytotoxic effects. In a mouse model for IgA nephropathy, Mizoribine was documented to influence the proliferation of B cells and decrease the glomerular IgA load while increasing glomerular expansion. In addition in human B cells the compound has been observed to Inhibit the expression of cyclin A. The immunosuppressive effects of Mizoribine Hydrobromide also effects T cells through suppression of G to S phase transition. In the case of puromycin aminonucleoside nephropathy Mizoribine demonstrated the ability to prevent podocyte injury. The compound has also been documented to induce the differentiation of promyelocytes on a mechansim relying on impaired guanine nucleotide synthesis. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
